Nanox (NASDAQ: NNOX) has entered into a distribution agreement with Costa Rica-based medical equipment distributor SOLME RC, S.A. to market and support the Nanox.ARC, a multi-source digital tomosynthesis system designed to expand access to 3D medical imaging. The agreement positions Nanox to penetrate a market where SOLME is a registered supplier to the Caja Costarricense de Seguro Social (CCSS), the country's principal purchaser and provider of hospital services.
The collaboration underscores Nanox's strategic push into Latin America, following distribution deals in Argentina and Peru earlier this year. Costa Rica represents the company's third Latin American market in 2026, signaling a broader effort to address underserved regions with affordable, scalable imaging technology. SOLME will oversee marketing, distribution, installation, training, and ongoing technical support, leveraging its established relationship with the CCSS to facilitate adoption.
Commercialization will proceed after applicable regulatory registration, including an initial six-month proof-of-concept device registration period before full registration. This phased approach allows for clinical validation and local acceptance, potentially smoothing the path to widespread deployment. The agreement's success hinges on regulatory approvals and the CCSS's adoption of the Nanox.ARC, but it aligns with Nanox's vision to drive preventive health care through integrated imaging solutions.
The Nanox ecosystem includes the Nanox.ARC, a cost-effective 3D multi-source digital tomosynthesis imaging system; Nanox.AI, a suite of AI-based algorithms that augment CT interpretation for early disease detection; Nanox.CLOUD, a cloud platform for secure data management and advanced analytics; Nanox.MARKETPLACE and USARAD Holdings, which provide remote radiology and cardiology expertise; and Nanox Health IT, which delivers RIS, PACS, AI, dictation, and secure infrastructure solutions. By integrating these components, Nanox aims to lower barriers to adoption, improve utilization, and advance preventive care worldwide.
This announcement matters because it highlights Nanox's continued expansion into emerging markets, where access to advanced medical imaging is often limited. By partnering with a local distributor that already supplies the CCSS, Nanox can navigate regulatory and procurement complexities more efficiently. The proof-of-concept period may serve as a template for future market entries, reducing risks associated with regulatory hurdles. Moreover, the deal reinforces Nanox's commitment to making 3D imaging more accessible, potentially improving early detection and patient outcomes in Costa Rica.
For investors, the agreement demonstrates progress in Nanox's commercialization strategy, though it remains subject to regulatory and operational risks. The company's forward-looking statements caution that actual results may differ materially due to various factors. Nonetheless, the move into Costa Rica adds to Nanox's growing footprint in Latin America, a region where demand for affordable imaging solutions is rising.
For more details, view the full press release at https://ibn.fm/C77lJ. The latest news and updates relating to NNOX are available in the company's newsroom at https://ibn.fm/NNOX. Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer.
